CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $1.84M, lower than 95% of all stocks globally
- PositionOperating margin is -14347%, lower than 95% of its Biotechnology peers (median -23.8%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.39BUSDvs all stocks (USD)
Revenue (TTM)
1.84MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.33xvs all stocks
52-Week Change
165.87%vs all stocks
Market Capitalization
1.39BUSDvs all stocks (USD)
Enterprise Value
1.16BUSDvs all stocks (USD)
Forward P/E
-13.22xvs Biotechnology peers
Price to Book (MRQ)
7.43xvs Biotechnology peers
Enterprise to Revenue
632.79xvs Biotechnology peers
Enterprise to EBITDA
-9.98xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-37.33%vs Biotechnology peers
Return on Equity (TTM)
-63.89%vs Biotechnology peers
Revenue (TTM)
1.84MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0130USDUpdated Jul 17, 2026Quarterly Revenue Growth
-81.80%vs Biotechnology peers
Gross Profit (TTM)
-81.79MUSDvs all stocks (USD)
EBITDA (TTM)
-116.44MUSDvs all stocks (USD)
Net Income (TTM)
-118.44MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-81.76%vs Biotechnology peers
Operating Cash Flow (TTM)
-97.39MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-41.48MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 17, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
2.80MUSDFY2025 · Dec 31, 2025Operating Income
-125.42MUSDvs all stocks (USD)
Pre-tax Income
-115.11MUSDFY2025 · Dec 31, 2025Income Tax Expense
69.00KUSDFY2025 · Dec 31, 2025Net Income
-115.18MUSDFY2025 · Dec 31, 2025EBIT
-114.91MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-108.26MUSDFY2025 · Dec 31, 2025Research & Development
81.42MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
35.06MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
209.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.8400USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.8400USDFY2025 · Dec 31, 2025Basic Shares Outstanding
136.78MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
136.78MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-115.18MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-91.05MUSDFY2025 · Dec 31, 2025Free Cash Flow
-91.26MUSDDerived from operating cash flow minus capital expenditure. This filing charges 11.74M of depreciation against 205K of capital expenditure, and its own free-cash-flow line reads -94.03M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
21.08MUSDFY2025 · Dec 31, 2025Interest Paid
178.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-115.18MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
11.74MUSDFY2025 · Dec 31, 2025Stock-based Compensation
18.32MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-5.68MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
0.00USDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-247.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
205.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-119.87MUSDFY2025 · Dec 31, 2025Sale of Investments
69.50MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-50.16MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-3.20MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
102.64MUSDFY2025 · Dec 31, 2025Shares Outstanding
155.35MSharesUpdated Jul 17, 2026Float Shares
148.72MSharesUpdated Jul 17, 2026Shares Short
36.94MSharesUpdated Jul 17, 2026Short Ratio
4.62daysvs all stocks
Short % of Shares Outstanding
26.61%vs all stocks
% Held by Insiders
12.04%vs all stocks
% Held by Institutions
73.01%vs all stocks
Total Cash (MRQ)
125.70MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.8060USDUpdated Jul 17, 2026Total Debt (MRQ)
4.42MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0257xvs Biotechnology peers
Current Ratio (MRQ)
6.59xvs Biotechnology peers
Book Value per Share (MRQ)
1.11USDUpdated Jul 17, 2026Total Assets
216.30MUSDvs all stocks (USD)
Total Current Assets
149.57MUSDFY2025 · Dec 31, 2025Total Liabilities
26.85MUSDFY2025 · Dec 31, 2025Total Non-current Assets
66.72MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
4.08MUSDFY2025 · Dec 31, 2025Total Current Liabilities
22.77MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
20.02MUSDFY2025 · Dec 31, 2025Other Short-term Investments
124.27MUSDFY2025 · Dec 31, 2025Accounts Payable
2.76MUSDFY2025 · Dec 31, 2025Short-term Debt
2.68MUSDFY2025 · Dec 31, 2025Deferred Revenue
739.00KUSDFY2025 · Dec 31, 2025Long-term Debt
2.62MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.02MUSDFY2025 · Dec 31, 2025Common Stock (Book)
15.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-624.78MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
189.45MUSDvs all stocks (USD)
52-Week Low
2.24USDUpdated Jul 17, 202652-Week High
12.05USDUpdated Jul 17, 202652-Week Change
165.87%vs all stocks
Beta
2.33xvs all stocks
50-Day MA
7.60USDUpdated Jul 17, 2026200-Day MA
4.41USDUpdated Jul 17, 2026Avg 10-Day Volume
4.82MSharesUpdated Jul 17, 2026Avg 30-Day Volume
7.08MSharesUpdated Jul 17, 2026Diluted EPS (TTM)
-0.8200USDUpdated Jul 17, 2026Other Income / Expense
10.51MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -14347%, lower than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: -143.47Industry median: -0.24Industry P5: -32.91Peers compared: 197
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $1.84M, lower than 95% of all stocks globallySignificant
Revenue (USD): 1,836,000Global P5: 30,274,777.221
Market cap is $1.39B, above the global median of $1.15BNotable
Market cap (USD): 1,394,164,740Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Qingdao Haier Biomedical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangxi Fushine Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai MicroPort EP MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chongqing Genrix Biopharma Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chongqing Taiji Industry Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
GenFleet Therapeutics (Shanghai) Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
KalVista Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
HBM Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Phibro Animal Health Corporation
Tier 1ProductionApproval-Gated PipelineRule
EL.En. S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Iovance Biotherapeutics, Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Twist Bioscience Corporation
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Hebei Sinopack Electronic Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity